Serenex Inc., a Durham, N.C.-based oncology drug company, has raised $26 million in Series D funding. It also has secured a $5 million working capital debt facility. New backers include Cornell Capital Partners, Pearl Street Ventures, MC Life Science Ventures and Pac-Link Bio Venture Capital. Returnees are Ritchie Capital, Intersouth Partners, Lilly Ventures, Mediphase Venture Partners, Takeda Research Investment and Seaflower Ventures. Serenex previously had raised around $60 million in total VC funding since its 2001 inception.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.